Please sign in using the form to the left to access these resources.
Devereux Reprint Devereux RB et al. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. Current Medical Research and Opinion. 2007;23:259-270.
One unit per package
(Limit 5 per month)
Salerno Reprint Salerno CM, Demopoulos L, Mukherjee R, Gradman AH. Combination Angiotensin Receptor Blocker/Hydrochlorothiazide as Initial Therapy in the treatment of Patients with Severe Hypertension.J Clin Hypertens. 2004;6:614–620.
One unit per package
(Limit 1 per month)
Gradman Reprint Gradman AH, Brady WE, Gazdick LP, Lyle P, Zeldin RK. A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertension. Clin Ther. 2002;24:1049–1061.
One unit per package
(Limit 5 per month)
No educational resources for patients are available at this time.
You can request a number of complimentary resources, where
available, including:
Patient Educational Materials
Disease Management Tools, and more
Signing in using the form to the left will give you access to educational resources for other products.
Access our archived eMedical Forum Webcasts, which are available for your viewing at any time.
Please sign in using the form to the left to access this service.
Important Product Information
HYZAAR is indicated for the treatment of hypertension. This fixed-dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients.
HYZAAR is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients.
Selected important cautionary information
HYZAAR is contraindicated in patients who are hypersensitive to any component of this product. Because of the hydrochlorothiazide (HCTZ) component, HYZAAR is also contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.
USE IN PREGNANCY: When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, HYZAAR should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality.
HYZAAR is not recommended for patients with severe renal impairment (creatinine clearance <30 mL/min). HYZAAR is not recommended as a means of titration for patients with hepatic impairment because the appropriate 25-mg starting dose of losartan cannot be given. In patients who are volume-depleted (eg, those treated with diuretics), symptomatic hypotension may occur after initiation of therapy with HYZAAR. This condition should be corrected prior to administration of HYZAAR.
The most common adverse events occurring with various doses of losartan/HCTZ (n = 858) at a rate >1% above placebo (n = 173) were upper respiratory infection (6% vs 5%), dizziness (6% vs 3%), back pain (2% vs 1%), palpitations (1% vs 0%), and rash (1% vs 0%).
COZAAR and HYZAAR are registered trademarks of E.I. du Pont de Nemours and Company, Wilmington, Delaware, USA
FOSAMAX PLUS D is a trademark of Merck & Co., Inc.
VYTORIN and ZETIA are registered trademarks of MSP Singapore Company, LLC. View the Merck/Schering-Plough privacy policy.
All other brand names are registered trademarks of Merck & Co., Inc.
MerckServices and MerckSource are registered trademarks of Merck & Co., Inc.
MerckProductServices and MerckMedicus are trademarks of Merck & Co., Inc.
Contact Us
Ask a Product-Related Question or Report an Adverse Event
Let us assist you with information and services related to Merck and its products. Get Started
requires a 
requires a 
HYZAAR® (losartan potassium-hydrochlorothiazide tablets)
